Genotype–phenotype relationships involving hypertrophic cardiomyopathy-associated mutations in titin, muscle LIM protein, and telethonin☆
Introduction
Affecting one in 500 persons, hypertrophic cardiomyopathy (HCM) is a disease associated with remarkable genotypic and phenotypic heterogeneity [1], [2]. Clinical outcomes range from an entirely asymptomatic course with normal longevity to chronic progressive heart failure or sudden cardiac death (SCD). Indeed, HCM is one of the leading causes of SCD in young persons [1].
The most common genetically mediated form of HCM is myofilament-HCM with hundreds of disease-associated mutations in eight genes encoding proteins critical to the sarcomere’s thick—[β-myosin heavy chain (MYH7) [3], regulatory myosin light chain (MYL2), and essential myosin light chain (MYL3)] [4], intermediate—[myosin binding protein C (MYBPC3)] [5], and thin myofilament [cardiac troponin T (TNNT2), α-tropomyosin (TPM1) [6], cardiac troponin I (TNNI3) [7], and actin (ACTC) [8], [9]]. Myofilament-HCM accounts for approximately 40–65% of HCM among cohorts of unrelated patients [10]. In general, patients with myofilament-HCM have greater hypertrophy and present at a younger age than those who remain without an established disease-causing mutation [11]. The two most common genotypes of myofilament-HCM, MYBPC3- and MYH7-HCM, are phenotypically indistinguishable from each other [12], [13], [14], [15], [16], [17], [18], [19], [20].
Besides perturbations involving the sarcomere’s myofilaments, the Z-disc, which comprises a cadre of proteins involved in cardiomyocyte cytoarchitecture and mechano-sensor-signaling, has emerged recently as host to several HCM-associated mutations extending the spectrum of “sarcomeric”-HCM. To date, three genes encoding critical Z-disc proteins: TTN-encoded titin, CSRP3-encoded muscle LIM protein (MLP), and the TCAP-encoded telethonin, have been implicated in the pathogenesis of both dilated cardiomyopathy (DCM) and HCM [21], [22], [23], [24].
As part of the cardiomyocyte stretch response machinery, TTN-encoded titin, which extends throughout half of the sarcomere from the M-line to the Z-disc is the largest of the three proteins; mapped on chromosome 2q31, TTN encodes for a giant 26,926 amino-acid protein with a molecular weight of 2993 kD [25]. CSRP3-encoded MLP and TCAP-encoded telethonin are mapped to chromosome 11p15.1 and 17q12, respectively, and contain 194 and 167 amino acids, respectively [26], [27]. Prior to this study, one HCM-associated mutation in TTN (R740L-TTN) [28], three HCM-associated mutations in MLP (L44P-MLP, C58G-MLP, and S54R/E55G-MLP) [22], and two HCM-associated mutations in TCAP (T137I-TCAP and R153H-TCAP) have been reported [21].
Having completed a comprehensive mutational analysis involving all translated exons of the eight genes responsible for myofilament-HCM [14], [15], [29], [30], we sought to determine the frequency, spectrum, and phenotype associated with these three genes that encode essential Z-disc proteins among a large cohort of unrelated patients diagnosed clinically with HCM.
Section snippets
Study population
Following a written informed consent for this IRB-approved research protocol, blood samples were obtained from 389 unrelated patients with HCM (215 male, left ventricular wall thickness of 21.6 ± 6 mm) evaluated at the Mayo Clinic’s HCM clinic between April 1997 and December 2001. Subsequently DNA was extracted from the blood samples using Purgene DNA extraction kits (Gentra, Minneapolis, Minnesota).
HCM-associated mutational analysis of TTN, CSRP3, and TCAP
Using polymerase chain reaction (PCR) and denaturing high performance liquid chromatography (DHPLC)
Results
Table 1 summarizes the phenotype of the entire HCM cohort including those with perturbations involving either MLP or telethonin. The mean age at diagnosis for our total cohort was approximately 41 ± 19 years with 216 patients (56%) having cardiac symptoms at presentation and 60 (15%) having received an implantable cardioverter-defibrillator (ICD). The mean maximum left ventricular wall thickness (LVWT) was 21.6 ± 6 mm. Of the 389, 161 (41%) were treated in part by a surgical myectomy, reflecting the
Discussion
As critical components of the dynamic protein scaffolding between the sarcomere and cytoskeleton at the Z-line, the titin-muscle LIM protein–telethonin complex is involved in both cyto-architecture and mechano-signaling, thus serving as a potential link between myofilament-HCM and Z-disc-HCM. Prior to this study, one HCM-associated mutation in titin [28], four HCM-associated mutations in MLP [22], [31] and two HCM-associated mutations in telethonin have been reported [21]. In addition,
Conclusions
In this study, HCM-susceptibility mutations in CSRP3 and TCAP represent uncommon causes of HCM, with a prevalence similar to troponin I- and actin-HCM. The combined clinical phenotype of MLP/TCAP-HCM resembles that of myofilament-HCM. Co-segregation and functional studies are now needed to dissect the relative contributions of the various Z-disc mutations to the pathogenesis and phenotypic expression of HCM.
Acknowledgments
We are grateful to the patients seen at the HCM clinic for their participation in this study and to Mr. Doug Kocer, the nurse coordinator of the HCM clinic.
References (36)
- et al.
A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation
Cell
(1990) - et al.
Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere
Cell
(1994) - et al.
Inherited and de novo mutations in the cardiac actin gene cause hypertrophic cardiomyopathy
J. Mol. Cell. Cardiol.
(2000) - et al.
Sarcomeric genotyping in hypertrophic cardiomyopathy
Mayo Clin. Proc.
(2005) - et al.
Yield of genetic testing in hypertrophic cardiomyopathy
Mayo Clin. Proc.
(2005) - et al.
Myosin binding protein C mutations and compound herterozygosity in hypertrophic cardiomyopathy
J. Am. Coll. Cardiol.
(2004) - et al.
Comprehensive analysis of the beta-myosin heavy chain gene in 389 unrelated patients with hypertrophic cardiomyopathy
J. Am. Coll. Cardiol.
(2004) - et al.
Spectrum of clinical phenotypes and gene variants in cardiac myosin-binding protein C mutation carriers with hypertrophic cardiomyopathy
J. Am. Coll. Cardiol.
(2001) - et al.
Identification of the genotypes causing hypertrophic cardiomyopathy in northern Sweden
J. Mol. Cell. Cardiol.
(2003) - et al.
The cardiac beta-myosin heavy chain gene is not the predominant gene for hypertrophic cardiomyopathy in the Finnish population
J. Am. Coll. Cardiol.
(1998)
Tcap gene mutations in hypertrophic cardiomyopathy and dilated cardiomyopathy
J. Am. Coll. Cardiol.
Titin mutations as the molecular basis for dilated cardiomyopathy
Biochem. Biophys. Res. Commun.
Telethonin, a novel sarcomeric protein of heart and skeletal muscle
FEBS Lett.
Mapping of a human LIM protein (CLP) to human chromosome 11p15.1 by fluorescence in situ hybridization
Genomics
Structural analysis of the titin gene in hypertrophic cardiomyopathy: identification of a novel disease gene
Biochem. Biophys. Res. Commun.
Prevalence and age-dependence of malignant mutations in the beta-myosin heavy chain and troponin T gene in hypertrophic cardiomyopathy: a comprehensive outpatient perspective
J. Am. Coll. Cardiol.
W4R variant in CSRP3 encoding muscle LIM protein in a patient with hypertrophic cardiomyopathy
Mol. Genet. Metab.
Identification and functional analysis of a caveolin-3 mutation associated with familial hypertrophic cardiomyopathy
Biochem. Biophys. Res. Commun.
Cited by (165)
The p.(Cys150Tyr) variant in CSRP3 is associated with late-onset hypertrophic cardiomyopathy in heterozygous individuals
2020, European Journal of Medical GeneticsIdentification of a novel titin-cap/telethonin mutation in a Portuguese family with hypertrophic cardiomyopathy
2020, Revista Portuguesa de CardiologiaCitation Excerpt :In the present study, however, we describe a family carrying a new TCAP mutation whose phenotype has neutral septal morphology. As shown by several studies, TCAP mutations identified in cardiomyopathy patients are distributed over the whole gene/protein10,31,33–38 (Figure 2A) and the differentiation between true pathogenic mutations and benign polymorphisms is challenging. One example is the in-frame deletion p.Glu13del initially described by Bos et al. as pathogenic,31 which we and many others have shown is benign because of its frequency.14,39
TCAP gene is not a common cause of cardiomyopathy in Iranian patients
2023, European Journal of Medical ResearchIdentification and in silico characterization of CSRP3 synonymous variants in dilated cardiomyopathy
2023, Molecular Biology Reports
- ☆
M.J.A.’s research program is supported by the Dr. Scholl Foundation, the CJ Foundation for SIDS, the Doris Duke Charitable Foundation, the American Heart Association, and the National Institutes of Health (HD42569). M.J.A. is an established investigator of the American Heart Association. M.V. is funded by the National Heart, Lung, and Blood Institute (1R21HL078807 and R21Hl077706) and the Italian Ministry of Education, University and Research (MIUR) D.M. 26.01.2001 #13. J.A.T. is supported by the Texas Children’s Foundation Chair in Cardiac Research grants from the National Institutes of Health (P01), the John Patrick Albright Foundation, and TexGen.